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Idiopathic pulmonary fibrosis (IPF) is a devastating disease that afflicts patients with relent-
lessly progressive shortness of breath [Joint Statement of the American Thoracic Society and
the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment.
Am J Respir Crit Care Med 2000;161:646e641]. Despite nearly 30 years of intense investiga-
tion, effective therapy for IPF remains elusive; median survival rates have stubbornly remained
less than five years from the time of diagnosis [Bjoraker JA, Ryu JH, Edwin MK, Meyers J, Ta-
zelaar H, Schroeder D, et al. Prognostic significance of histopathologic subsets in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199e2032, Flaherty KR, Thwaite E, Ka-
zerooni EA, Gross B, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UIP
and NSIP: survival implications. Thorax 2003;58:143e483], and no medical therapy has been
proved to be in any way effective for the treatment of this disease. Without medications that
help IPF patients live longer, an important question to ask is whether there are interventions
that might allow these people to live betterdto be more active; to experience less dyspnea,
less depression, less anxiety; to possess a greater sense of control over their disease; and to
have better quality of life. Pulmonary rehabilitation helps to accomplish many of these goals
in patients with chronic obstructive pulmonary disease, and emerging data suggest that it may
do the same for patients with IPF.
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Idiopathic pulmonary fibrosis (IPF) is the most common
subtype of the so-called idiopathic interstitial pneumo-
niasda cluster of inflammatory and/or fibrosing interstitial
lung diseases (ILDs) with potentially similar presentations
but differing prognoses. Conventional pharmacotherapy for
IPF is ineffectivedno therapy has been shown to prolong
life; improve lung function, exercise, or functional
capacity; decrease symptoms; or make QOL better.
Persistent investigation for effective therapy has not
altered the median survival of IPF patientsdit remains
startlingly short and similar to some malignancies, between
three and five years from the time of diagnosis.2
IPF-related morbidity
IPF potentially leads to a number of morbidities or sequelae
(e.g., dyspnea, exercise limitation, fatigue, anxiety and
mood disturbance, impaired QOL) that dramatically impact
patients’ lives.
Dyspnea
The hallmark symptom of IPF is dyspnea.1 Because of
breathlessness, patients experience the ability to do less
physically, the need to pace themselves while performing
any physical activity, the need to rest more frequently, and
they need more time to recover after exerting.4 Clearly,
dyspnea impairs patients with IPFdit measurably worsens
over time5 and appears to be one driver of QOL.6
Exercise limitation and fatigue
Decreased ventilatory capacity, gas exchange inefficiency,
and impaired oxygen transport may all contribute to exer-
cise limitationdand, more generally, decreased physical
functional capacitydin patients with IPF.7,8 Patients with
IPF are not only breathless and unable to exert to the
degree they would like, but also they are fatigued. In fact,
patients describe the symptom as exhaustion.4 The degree
of fatigue or exhaustion in patients with IPF has never been
quantified, but it appears to be very common, incrediblyintrusive,9 and at least as frustrating to patients as short-
ness of breath.
Anxiety and mood disturbance
IPF patients report feeling sadness, fear, worry, anxiety,
and panicdIPF has the effect of ‘‘turning life upside-
down.’’4 In a couple studies, investigators administered the
Hospital Anxiety and Depression scale; IPF patients’ scores
were higher than controls’ but not diagnostic for the
presence of anxiety or depression.10,11 In several other
cross-sectional studies, investigators have administered
QOL instruments (e.g., the SF-36 or Saint George’s Respi-
ratory QuestionnairedSGRQ) to patients with IPF. In those
studies, investigators identified impaired QOL in domains
that tap mood and emotions (e.g., the SF-36 ‘‘Mental
Health’’ domain that assesses the frequency of feeling
nervous, down in the dumps, blue/sad, peaceful, or happy;
and the SGRQ ‘‘Impacts’’ domain that assesses the impact
of disease on, among other things, inducing feelings of
embarrassment, fear or panic).6,12,13
QOL
Given the intrusive symptoms and reduced functional
capacity that plague people with IPF, it is not surprising
that these patients’ QOL is impaired. The extent to which
IPF encroaches on every aspect of patients’ lives is reflec-
ted in their poor QOL scores from nearly every QOL domain.
And no therapy or other intervention has been shown to
improve any aspect of QOL.14 The greatest impairments in
QOL appear to be in physical health domains. However,
scores from mental health domains also suggest worse
quality of emotional and mental health than people from
the general population.13,14 Thus, patients with IPF live
with poor quality while they are dying from this disease.
Pulmonary rehabilitation
Pulmonary rehabilitation (PR) is a comprehensive, multi-
disciplinary program that uses a combination of teaching,
counseling, and behavior modification techniques to
improve self-management, reduce symptoms, optimize
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Figure 1 Hypothesized impact of pulmonary rehabilitation in
patients with IPF.
PR for IPF 1677functional capacity, and increase participation in patients
with chronic lung disease.15 Typical PR programs offer an
intense component (variable time period, often 6e10
weeks) followed by a maintenance component for those
patients who wish to continue to participate. Usually,
rehabilitation staff performs a comprehensive assessment
of patients’ physical strengths and deficiencies along with
their emotional and other needs prior to enrollment. An
exercise and overall intervention (e.g., psychosocial,
nutritional) program is tailored to the individual, and the
patient returns to the center 2e3 times per week to
complete it in a setting with close monitoring by staffd
usually physical or respiratory therapists.
In patients with chronic obstructive pulmonary disease
(COPD), PR is a cornerstone of active treatment. An enor-
mous and growing body of evidence has demonstrated the
exercise-limiting effects of COPD; in the lungs, these
include delayed air emptying,16 dynamic hyperinflation,17
and increased respiratory muscle load.18 Cardiac dysfunc-
tion may also be present; for example, right ventricular
afterload and the potential for tachyarrythmias increase
with exercise, and cardiac deconditioning is likely present in
most patients with COPD (and other chronic lung diseases).
Body weightdincluding skeletal muscle massdloss is not
uncommon, effecting about 30% of COPD patients.19 Early
contractile fatigue (particularly in the quadriceps20), likely
related to myriad complex and intersecting metabolic
derangements,15 affects the efficiency of skeletal muscles.
Finally, there is compromised inspiratory muscle strength
and endurance. All of these factors contribute to exercise
limitation in patients with COPD.
Components of PR target many of these limiting factors.
For example, pursed-lip breathing (PLB) aims to decrease
respiratory rate (prolong expiration) and dyspnea while
increasing tidal volume and oxygen saturation.21 The
exercise component of PR has several potential beneficial
effects including improving cardiac conditioning, increasing
fat-free body mass,22 making the quadriceps more fatigue
resistant23; and enhancing the efficiency of skeletal muscle
function at the cellular and molecular levels.15
From a clinical outcomes standpoint, PR has been shown
to not only improve exercise capacitydas measured
by distance walked during a 6-min walk test (6MWT) or by
oxygen uptake during a maximal cardiopulmonary exercise
test (Vo2max)dbut QOL and dyspnea as well.
15 Moreover,
emerging data suggest that PR improves psychological
adjustment and cognitive impairment in patients with
COPD.24e26
Why might pulmonary rehabilitation help patients
with IPF?
Although IPF and COPD are, in many respects, drastically
different diseases, they are also similar in many ways:
patients with COPD have some of the same limitations as
patients with IPF. For example, both have impaired lung
mechanics, increased work of breathing, and abnormal gas
exchange. As is likely true for patients with IPF, those with
COPD also have higher-than-expected rates of anxiety and
depressiondmuch greater than rates in general medical
patients or in people from the communitydand in many
studies with rates approaching 50%.27e29 Patients withCOPD have impaired QOL; for a given degree of disease
severity, patients with IPF appear to have impairments in
QOL that are at least as severe asdif not more severe
thandpatients with COPD.14
Given these similarities, it seems plausible that patients
with IPF might receive the same benefit from PR that patients
with COPD receive; Fig. 1 illustrates possible important
domains of benefit. We believe a large study would show that
PR would improve functional capacity (as measured by 6-min
walk), dyspnea for a given level of exertion, anxiety, mood,
fatigue, and QOL in patients with IPF.
Early data suggest that PR might improve certain
important outcomes in patients with IPF; for example, in
pilot studies, PR lengthened distance walked during
a 6MWT (i.e., 6MWD) or 12-min walk test,30 and decreased
dyspnea (e.g., as measured by the Borg scale at the end of
a 6-min walk test).31e35 Deficient in the literature are
systematic studies that have examined PR in patients with
IPF, but it appears as though interest in this intervention for
IPF is growing. There are at least two studies of PR for IPF
currently registered at www.clinicaltrials.gov, and there
have been a handful of abstracts focused on this topic in
patients with interstitial lung disease (many presumably
with IPF) presented at recent meetings.30e35
Two published small studies suggest that PR leads to
improvements in dyspnea and certain quality of life
domains in patients with restrictive lung disease (including
some with IPF).10,36 For example, Jastrzebski and
colleagues studied 38 subjects with various ILD, including
13 with IPF. The intervention consisted of a four-week
in-hospital program that was continued by patients at home
for up to 12 weeks.36 The exercise program consisted of
twice weekly, 30-min sessions that included respiratory
muscle exercise and cycle ergometry, starting at 60% of
maximum workload and continuing to fatigue. Compared
with baseline, post-PR Borg scores were significantly (only
0.5 points) lower, but there were no significant improve-
ments in dyspnea according to other scales. There was
better QOL after PR according to certain domains of the
SF-36 and SGRQ. Naji and co-investigators studied the
effects of an eight-week PR program in 46 subjects with
restrictive lung disease, including 28 with IPF.10 Only 26
subjects (19 ILD, number with IPF not stated) completed
the eight-week program, and only 15 (10 ILD, number with
IPF not stated) returned for retesting at one year. At eight
weeks, significant improvements over baseline were
observed in treadmill duration test (22.7 11.7 min vs.
12.7 9.5 min, p< 0.0001), shuttle test, dyspnea, QOL as
1678 J.J. Swigris et al.measured by the Chronic Respiratory Questionnaire, and
depression. At one year, the treadmill test remained
significantly better than baseline (20.3 12.5 min vs.
12.7 9.5 min, p< 0.02), but effects waned in all other
outcomes.
Two recently published studies compared the effects of
exercise in subjects with IPF vs. IPF controls.37,38 Neither
study included other aspects of PR (e.g., education,
breathing training, psychosocial support, nutrition, etc.) in
their interventions. In one of these studies, Nishiyama and
colleagues randomized 13 subjects to an exercise program
(as might be implemented in PR) and compared their
change in 6MWD (from baseline to completion of the
program) with 15 IPF controls. The 10-week program
consisted of exercising on the treadmill at 80% maximal
walking speed or 80% maximum workload (as assessed by
maximal exercise test) along with upper and lower
extremity strength training with elastic bands. At 10 weeks,
6MWD in IPF subjects improved, while 6MWD in controls was
unchanged, yielding a between group difference of 46.3 m
(95% CI 8.3e84.4, p< 0.01). Similarly, QOL improved in
subjects and remained unchanged in controls. In a study
focused on longer-term outcomes after an exercise
program, Holland and her colleagues randomized 57
subjects with ILD (34 with IPF) to an eight-week exercise
program (NZ 30) or to weekly telephone support
(NZ 27).37 The twice weekly exercise program sessions
consisted of cycle ergometry and walking at 80% of
maximum speed for 30 min, upper limb endurance training,
and lower limb strength training. Twenty-four subjects in
the exercise group completed the program that led to
improved 6MWD (mean 35 m, 95% CI 6e64, p< 0.05Z
0.01), dyspnea, and QOL at nine weeks compared with
controls. None of these beneficial effects remained at six
months. The effects of exercise in subjects with IPF,
seemed not to be as great as in subjects with non-IPF ILD;
for example, at nine weeks, 6MWD improved an average of
25.1 m in subjects with IPF compared with 43.5 m in
subjects with non-IPF ILD. From 9 to 26 weeks, 6MWD
declined an average 44.2 m in subjects with IPF and 20.8 m
in subjects with non-IPF ILD (pZ NS).
A conceptual framework for how PR might
work in IPF
Despite the absence of numerous or large-scaled systematic
investigations, based on available data, scientific rationale,
and what is known in COPD, a multi-national committee of
IPF experts (and a similar group of PR experts15) has
recommended that IPF patients participate in traditional
PR programs.1
We hypothesize that PR benefits patients with IPF by
interrupting several pathways leading to sequelae or
co-morbidities (Fig. 2). In IPF patients, various emotional
health issues (e.g., a sense of no control over the disease
process, fear and anxiety, and impaired QOL) likely exist
simply from having to live with a disease like IPF; that is,
they occur through mechanisms not entirely driven by
physical symptoms or physiologic abnormalities.
We suspect that the improved walk distance after PR in
IPF patients stems from better overall cardiovascular
fitness resulting from the aerobic exercise regimen. It
would seem reasonable to expect the same beneficialeffect on skeletal muscle in IPF patients as in COPD
patients. Less dyspnea during exercise may develop when
patients increase their self-exposure to the ‘‘dyspneic
state’’dperhaps increased time in this state actually
desensitizes the perception.39 Pursed-lip breathing is an
important component of PR in patients with COPD; whether
PLB benefits patients with IPF is unknown. Because the
physiology of IPF is different, PLB per say may not work (or
may not work physiologically as it does in COPD), but the
emphasis on respiratory control and diaphragmatic
inputdthe cornerstones of the pursed-lip techniquedmay
benefit IPF patients by decreasing fear, anxiety, tachypnea
and improving gas exchange.
PR might improve other important outcomes in patients
with IPF as well. For example, resistance training would be
expected to improve general muscle strength and tone. The
processes of committing to a program, participating, and
interacting with people facing similar challenges might help
patients develop some sense of control over disease; alle-
viate fear and anxiety; improve mood and psychological
function; and generally boost QOL. Anecdotally, we have
found all of these to be true: IPF patients who return to
clinic after completing PR have an improved sense of well-
being compared with prior to enrolling in PR. They have
a greater sense of control; they develop confidence that
physical activity is not harmful; they find themselves doing
more; they have more energy; and their general outlook on
life is better. Hence, available, albeit limited evidence,
suggests that, in patients with IPF, as in patients with
COPD, PR improves multiple important clinical outcomes.
Future research directions
Continued systematic investigation into PR for IPF could
help to answer several lingering questions. For example, in
which areas and to what extent are the beneficial effects of
PR realized in patients with IPF? What are the important
predictors of benefit in this patient population? What
variables (patient characteristics) might impede patients
from receiving full benefits of PR? Determining with greater
certainty whether and how PR can help patients with IPF
will require systematic investigation in well-designed
studies. Ideally, multi-centered, controlled studies would
be designed to evaluate the effects of PR in patients with
IPF. In the process, an important question will need to be
addressed: how to implement a similar program across
centers? Second, what is an appropriate control group for
such a study? Investigators in the National Emphysema
Treatment Trial (NETT)40 demonstrated that a comprehen-
sive PR program could be reliably employed across multiple
centers by using a cluster of core sites. Those sites had the
jobs of implementing the PR program for local subjects,
training surrounding participating sites on program
specifics, and maintaining quality control. This required
a great deal of manpower, but NETT showed that it could be
done.
Another enormously important question is what should
a PR program for patients with IPF entail? As for patients
with COPD, for patients with IPF, PR should be a multi-
disciplinary program with a disease-specific educational
component; a strong behavioral health component to
include instruction on coping skills, along with
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Figure 2 Pathways to sequelae or co-morbidities in IPF.
PR for IPF 1679a comprehensive management plan for stress, anxiety, and
depression; a nutrition assessment and intervention
program; and aerobic and resistance exercise training. It is
not knowndand will require further detailed explor-
ationdwhether or how the traditional approach to PR-
related exercise training (designed with the COPD patient
in mind) will benefit patients with IPF. The obvious patho-
physiological differences between COPD and IPF raise
concerns that a unique approach to exercise training may
be required for patients with IPF to benefit maximally.
Specifically, endurance training with PLB is well-suited to
balance the airflow limitation, large lung volumes, air-
trapping, and increased resistance work of breathing in
patients with COPD, allowing them to maximally benefit
from PR. However, the type of exercise (e.g., interval as
opposed to endurance training) and breathing technique (if
any) that allows maximal benefit in patients with IPF are
unknown.
Non-exercise (or non-physical functionality) outcomes,
for which PR has demonstrated benefit in patients with
COPD, should be further examined in patients with IPF. It
will be important to learn whether the positive effects of
PR on QOL, mood, and cognition that have been observed in
patients with COPD will also be seen in patients with IPF. Of
course, seeing these benefits require the use of instruments
with adequate and appropriate vision; that is, instruments
with the ability to measure what they purport to measure
(i.e., validity) and the sensitivity to detect underlying
change (i.e., responsiveness). In the case of QOL, these
characteristics are most assured with disease-specific
measures; for COPD there are several, but for IPF, there are
none. An IPF-specific QOL instrument would likely be very
helpful. Assuming that PR benefits patients with IPF, a few
final important questions to ask are: what is the optimal
duration of the program? How long will the putative bene-
fits last, and how might the beneficial effects be made to
last longer?Conclusion
Like COPD, IPF is a devastating disease that leads to
significant physical, functional, and emotional sequelae.
Although conventional pharmacotherapy has proved to be
widely unsuccessful in benefiting IPF patients, pulmonary
rehabilitation may hold promise for making impacts in areas
that are most important to patients. Future research should
aim to answer whether and how PR might benefit IPF
patients; to define the features associated with maximal
benefit from PR; to identify barriers to maximal benefit and
ensure that interventions targeting these barriers are in
place prior to IPF patients enrolling in PRdan intervention
that appears to currently hold the most promise for
improving IPF patients’ lives on multiple important fronts.
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